

1636
#



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

TELEPHONE: 512/474-3601
FACSIMILE: 512/536-4339
STEVEN L. HIGHLANDER
PARTNER
INTERNET ADDRESS:
SHIGHLANDER@FULBRIGHT.COM
DIRECT DIAL: 512/536-3184

RECEIVED


MAR 12 2002

February 21, 2002

TECH CENTER 1600/2900

FILE: IOWA:042USD1
10107932

COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
February 21, 2002 Date	 Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

RE: SN 09/612/809 "THERAPEUTICS AND DIAGNOSTICS FOR CONGENITAL HEART DISEASE BASED ON A NOVEL HUMAN TRANSCRIPTION FACTOR" - By Val C. Sheffield

Commissioner:

Enclosed for filing in the above-referenced patent application is:


1. Amendment and Request for Reconsideration Under 37 C.F.R. §1.111;
2. A Request for an Extension of Time of three months to and including February 21, 2002;
3. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
4. Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Dated June 29, 2001;
5. Statement as Required Under 37 C.F.R. § 1.821(f); Paper Copy of Sequence Listing; Computer Readable Form (CRF); and
6. A check for \$920.00 as the fee for the extension of time; and

Commissioner for Patents
February 21, 2002
Page 2

7. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

If the check is inadvertently omitted, or the amount is insufficient, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or should an overpayment be included herein, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski L.L.P. Account No.: 50-1212/10107932/SLH.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642

SLH/cpj
Encl.:

RECEIVED

MAR 12 2002

TECH CENTER 1600/2900



CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

February 21, 2002
Date

Steven L. Highlander
Signature

COPY OF PAPERS
ORIGINALLY FILED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Val C. SHEFFIELD et al.

Serial No.: 09/612,809

Filed: July 10, 2000

For: THERAPEUTICS AND DIAGNOSTICS
FOR CONGENITAL HEART DISEASE
BASED ON A NOVEL HUMAN
TRANSCRIPTION FACTOR

Group Art Unit: 1636

Examiner: SCHARWTZMAN, R.

Atty. Dkt. No.: IOWA:042USD1/SLH

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES DATED AUGUST 21, 2001**

Commissioner for Patents
Washington, D.C. 20231

Commissioner:

This paper is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated August 21, 2001 for which the three-month date for response was November 21, 2001.

A request for a three-month extension of time to respond is included herewith along with the required fee. This three-month extension will bring the due date to February 21, 2002, which is within the six-month statutory period. Should such request or fee be deficient or absent, consider this paragraph such a request and authorization to withdraw the appropriate fee under


37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10107932/SLH.

RESPONSE TO NOTICE

Submitted herewith is a Statement As Required Under 37 C.F.R. § 1.821(f); paper copy of sequence listing and computer readable form (CRF) which comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

Applicants believe that the attached documents fully respond to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures for this application.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201
(512) 536-4598 (facsimile)

Date: February 21, 2002